News

Kapidex, available in 30mg and 60mg doses, was recently approved by the FDA for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing

The appointment concludes the executive search undertaken by the board of directors in November 2008 to identify a replacement for Richard Damron, Jr, who served in the same

The Phase II trial, also called the ‘Precedent study’, will evaluate the efficacy and safety of EC145 when administered in combination with pegylated liposomal doxorubicin (PLD). PLD is

In this position, Mr Lytton will be responsible for leading the company’s business development activities. From 2001 to 2009, Mr Lytton served as a general partner at Oxford

The purchase price of the Alveolus assets is approximately $19 million, subject to post-closing adjustments. The Alveolus assets consist primarily of an intellectual property portfolio, inventory, receivables and

Results of a study conducted by a research group at The University of Hong Kong through a collaboration with Novavax showed 100% survival of mice immunized with this

Under the agreement Dalton will continue to provide chemistry services in support of Boehringer’s pharmaceutical development programs. Peter Pekos, president of Dalton Pharma Services, said: “We are extremely

Data from this study will be used to further establish the optimal dose regimen for MoxDuo IR, select an appropriate control group, and properly design an upcoming pivotal

The trial is being conducted under a special protocol assessment, which is an agreement between the FDA and Seattle Genetics regarding the trial design necessary to support an